Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics
The DC internalization and activation assays described here address key gaps in existing immunogenicity assessment methods by providing specific and reliable measures of DC function. The assays enhance our ability to pre-clinically evaluate the immunogenic potential of biotherapeutics, thereby improving their safety and efficacy. Future work should focus on further validating these assays and integrating them into a holistic immunogenicity risk assessment framework.
Authors
- Anna‐Lena Bolender
- Katharina Hartman (ORCID: https://orcid.org/0009-0006-0509-516X)
- Aman Padamsey
- Cary M. Looney
- Céline Marban-Doran
- Axel Ducret (ORCID: https://orcid.org/0000-0003-1251-8520)
- Cristina Bertinetti‐Lapatki
- Thomas E. Kraft (ORCID: https://orcid.org/0000-0002-5528-3197)
- Michel Siegel (ORCID: https://orcid.org/0009-0003-2858-4247)
- Timothy P. Hickling (ORCID: https://orcid.org/0000-0002-8918-2140)
- Olivier Rohr (ORCID: https://orcid.org/0000-0001-8992-2025)
- Johannes Fraidling
- Patrick Hargreaves
Institutions
- Roche (Switzerland) (CH)
- Centre National de la Recherche Scientifique (FR)
- Roche Pharma AG (Germany) (DE)
- Instituts Universitaires de Technologie (FR)
- Architecture et Réactivité de l'arN (FR)
- Université de Strasbourg (FR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-08-20
- DOI
- https://doi.org/10.3389/fimmu.2024.1406804
- Citations
- 5
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.20
Funders
- Genentech